Page last updated: 2024-08-21

indazoles and entrectinib

indazoles has been researched along with entrectinib in 106 studies

Research

Studies (106)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	32 (30.19)	24.3611
2020's	74 (69.81)	2.80

Authors

Authors	Studies
Ali, SM; Balasubramanian, S; Do, IG; Hong, JY; Hornby, Z; Huh, JW; Jang, J; Kang, WK; Kim, HC; Kim, KM; Kim, SH; Kim, ST; Kim, SY; Lee, J; Lee, WY; Li, GG; Lim, HY; Miller, VA; Ou, SH; Park, JO; Park, YA; Park, YS; Ross, JS; Stephens, PJ; Wang, K; Yun, SH	1
Giallombardo, M; Gil-Bazo, I; Giovannetti, E; Passiglia, F; Peeters, M; Raez, L; Rolfo, C; Ruiz, R; Russo, A	1
Ahn, SM; Christiansen, J; Hong, ME; Hong, SN; Hornby, Z; Jang, J; Kang, WK; Kim, KM; Kim, SH; Kim, ST; Lee, DW; Lee, J; Lee, SJ; Li, GG; Lim, HY; Murphy, D; Park, JO; Park, K; Park, WY; Park, YS; Wei, G; Yoon, N	1
Bardelli, A; Bartolini, A; Bianchi, AS; Cam, N; Corti, G; Crisafulli, G; Di Nicolantonio, F; Lazzari, L; Li, G; Misale, S; Mussolin, B; Novara, L; Patel, R; Rospo, G; Russo, M; Shoemaker, R; Siena, S; Siravegna, G; Wei, G; Wild, R; Yan, S	1
Bauer, TM; Chow-Maneval, E; Costa, DB; Drilon, A; Farago, AF; Hornby, Z; Iafrate, AJ; Jackman, D; Le, LP; Li, GG; Lim, JE; Liu, SV; Luo, D; Multani, PS; Muzikansky, A; Ou, SH; Patel, M; Shaw, AT; Zheng, Z	1
Amatu, A; Ardini, E; Bosotti, R; Buonandi, P; Cerea, G; Galvani, A; Giannetta, L; Hornby, Z; Isacchi, A; Lauricella, C; Luo, D; Maiolani, M; Marrapese, G; Multani, P; Murphy, D; Sartore-Bianchi, A; Shoemaker, R; Siena, S; Somaschini, A; Valtorta, E; Vanzulli, A; Veronese, S	1
Aveic, S; Esposito, MR; Li, G; Pantile, M; Seydel, A; Tonini, GP; Zanon, C	1
Brodeur, GM; Cam, N; Croucher, JL; Golden, RL; Guan, P; Hornby, Z; Iyer, R; Kolla, V; Li, G; MacFarland, SP; Naraparaju, K; Wehrmann, L; Wei, G	1
Arcila, M; Bauer, T; Berger, M; Cam, NR; Christiansen, J; Dogan, S; Drilon, A; Farago, A; Ghossein, R; Gounder, M; Hechtman, J; Ho, AL; Hornby, Z; Hyman, DM; Katabi, N; Ladanyi, M; Li, G; Lim, J; Liu, SV; Luo, D; Maneval, EC; Multani, P; Ou, SH; Patel, M; Shaw, A; Shen, R; Shoemaker, RF; Wang, L; Wei, G	1
Amboldi, N; Anderson, D; Ardini, E; Avanzi, N; Ballinari, D; Bandiera, T; Banfi, P; Bosotti, R; Casero, D; Ciomei, M; De Ponti, C; Degrassi, A; Donati, D; Felder, E; Galvani, A; Harris, J; Isacchi, A; Li, G; Magnaghi, P; Menichincheri, M; Mologni, L; Orsini, P; Pesenti, E; Pulci, R; Saccardo, MB; Texido, G; Vernier, JM; Wei, G	1
Ardini, E; Avanzi, N; Banfi, P; Borgia, AL; Bossi, R; Buffa, L; Canevari, G; Ceriani, L; Colombo, M; Corti, L; Donati, D; Fasolini, M; Felder, E; Fiorelli, C; Fiorentini, F; Galvani, A; Isacchi, A; Magnaghi, P; Marchionni, C; Menichincheri, M; Nesi, M; Orrenius, C; Orsini, P; Panzeri, A; Perrone, E; Pesenti, E; Rusconi, L; Saccardo, MB; Vanotti, E	1
Farago, AF; Holla, VR; Hong, DS; Khotskaya, YB; Meric-Bernstam, F; Mills Shaw, KR	1
Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M	1
Amatu, A; Bardelli, A; Bartolini, A; Buscarino, M; Cassingena, A; Corti, G; Crisafulli, G; Di Nicolantonio, F; Erlander, M; Mussolin, B; Novara, L; Sartore-Bianchi, A; Siena, S; Siravegna, G; Tosi, F	1
Benezra, R; Cook, PJ; de Leon, ES; Drilon, A; Kannan, R; Rosenblum, MK; Scaltriti, M; Thomas, R; Ventura, A	1
Bao, F; Christiansen, J; Foley, P; Hornby, Z; Luo, D; Maneval, EC; Multani, P; Sigal, D; Tartar, M; Xavier, M	1
Bonvini, P; Fagan, PC; Frasson, C; Germano, G; Li, G; Pomari, E; Silverman, I; Smith, KM; Walsh, C	1
Deng, S; Han, R; Liu, T; Wu, D; Xie, H; Xu, Y; Zhang, T	1
Arai, S; Fukuda, K; Furuya, N; Kinoshita, T; Kita, K; Nishiyama, A; Tajima, A; Takeuchi, S; Tange, S; Tanimoto, A; Wang, R; Yamada, T; Yano, S	1
Curiel-García, Á; Graña-Castro, O; Huse, JT; Marques, C; Matia, V; Oldrini, B; Rodriguez-Perales, S; Squatrito, M; Torres-Ruiz, R; Uluçkan, Ö	1
Chen, B; Zhou, F	1
Alrabiah, H; Attwa, MW; Darwish, HW; Kadi, AA	1
Macy, ME; Pacenta, HL	1
Ahn, JS; Ahn, MJ; Bae, YH; Ku, BM; Lee, KY; Lee, SH; Park, K; Sun, JM	1
Al-Salama, ZT; Keam, SJ	1
Fujita, N; Gong, B; Hanzawa, H; Hata, AN; Isoyama, T; Iwasaki, S; Kagoshima, Y; Kamai, Y; Katayama, R; Kiga, M; Koike, S; Miyamoto, M; Nakao, N; Nishio, M; Oh-Hara, T; Seto, Y; Shaw, AT; Shimizu, Y; Takeda, Y; Togashi, N; Tominaga, Y; Watanabe, K; Yanagitani, N; Yoda, S	1
Berger, MF; Cocco, E; Cownie, J; de Stanchina, E; Drilon, A; Ebata, K; Guzman, S; Hechtman, JF; Houck-Loomis, B; Hyman, DM; Kulick, A; Ladanyi, M; Lanman, RB; Mattar, M; Misale, S; Nagy, RJ; Patel, JA; Ptashkin, R; Razavi, P; Samoila, A; Scaltriti, M; Schram, AM; Selçuklu, SD; Shifman, S; Somwar, R; Toska, E; Tuch, BB; Won, HH; Yaeger, R	1
Davare, MA; Druker, BJ; Joshi, SK; Tognon, CE	1
Mullard, A	1
Drilon, A	1
Aschenbrenner, DS	1
Lassen, U	2
Jørgensen, JT	1
Barve, M; Bazhenova, L; Besse, B; Blakely, CM; Bowles, DW; Buchschacher, GL; Chae, YK; Chawla, SP; Cho, BC; Chow-Maneval, E; Conkling, P; Cui, N; Demetri, GD; Doebele, RC; Drilon, A; Eng, S; Fakih, M; Farago, AF; Fox, E; Garrido, P; Garrido-Laguna, I; John, T; Johnson, A; Krauss, JC; Liu, SV; Loong, HH; Nieva, J; Overbeck, TR; Paz-Ares, L; Riehl, T; Seto, T; Shaw, AT; Siena, S; Sigal, D; Simmons, B; Steuer, C; Tosi, D; Wilson, TR	1
Ahn, MJ; Arkenau, HT; Barlesi, F; Chae, YK; Chiu, CH; Cho, BC; Chow-Maneval, E; Chung, CH; Cui, N; de Braud, F; Doebele, RC; Drilon, A; Dziadziuszko, R; Eng, S; Goto, K; John, T; Johnson, A; Karapetis, CS; Kim, SW; Krebs, MG; Li, YC; Lin, CC; Murakami, H; Ohe, Y; Otterson, GA; Patel, MR; Prenen, H; Riehl, T; Rolfo, C; Seto, T; Shaw, AT; Siena, S; Simmons, B; Tan, DSW; Wilson, TR; Wolf, J	1
Brodeur, GM; Guan, P; Hu, Y; Iyer, R; Kolla, V; MacFarland, SP; Naraparaju, K; Tan, K	1
André, T; Cohen, R; Ouali, K; Pellat, A; Penault-Llorca, F; Svrcek, M	1
Bailey, JJ; Jaworski, C; Schirrmacher, R; Tung, D; Wängler, B; Wängler, C	1
Cerea, G; Marrapese, G; Pizzutilo, EG; Sartore-Bianchi, A; Siena, S; Tosi, F	1
Barbacid, M	1
Bisson, WH; Bottomly, D; Davare, MA; Druker, BJ; Huang, A; Joshi, SK; McWeeney, SK; Qian, K; Tognon, CE; Traer, E; Tyner, JW; Watanabe-Smith, K	1
Carlson, JJ; Roth, JA; Sullivan, SD; Williamson, T; Xia, F	1
Adhikary, R; Hussain, T; Khandelwal, R; Nayarisseri, A; Singh, SK	1
de la Cruz, CC; Donzelli, M; Draganov, D; Fischer, H; Hunsaker, T; Merchant, M; Paehler, A; Senn, C; Ullah, M; Vazvaei, F; Wagner, B; Wirz, T; Yu, L	1
Djebli, N; Guerini, E; Kowalski, K; Lindenberg, M; Meneses-Lorente, G; Parrott, N; Stillhart, C; Wagner, B	1
Hofman, J; Morell, A; Novotna, E; Vagiannis, D; Yu, Z	1
Huang, PH; Jones, RL; Loong, HH; Wilding, CP	1
Arkenau, HT; Coleman, N; Popat, S; Welsh, L; Yousaf, N	1
Ahn, JS; Ahn, MJ; Jung, HA; Lee, J; Lee, SH; Park, K; Park, S; Sun, JM	1
Battistone, B; Garrido-Laguna, I; Ghazi, P; Kinsey, CG; McMahon, M; Parkman, GL; Scherzer, MT; Schuman, S; Truong, A; Vaishnavi, A	1
Anyaegbu, G; Bentley, H; Bulusu, VR; Hatcher, H; Horan, G; Watkins, J; Wong, HH	1
Ardini, E; Siena, S	1
Walker, A	1
Aungst, S; Donoghue, M; Helms, WS; Keegan, P; Marcus, L; Myers, CE; Pazdur, R; Shen, G; Stephens, O; Zhao, H	1
Fan, Q; Li, Q; Liu, F; Ma, J; Zhang, B; Zhao, B	1
Eid, R; Haddad, FG; Kourie, HR	1
Delaye, M; Rodrigues, M	1
Asher, M; Benayed, R; Bowman, AS; de Stanchina, E; Hartono, AB; Hmeljak, J; Jungbluth, A; Khodos, I; Ladanyi, M; LaQuaglia, MP; Lee, SB; Magnan, H; Mattar, MS; Momeni Boroujeni, A; Odintsov, I; Ogura, K; Pratilas, CA; Slotkin, E; Somwar, R; Spraggon, L	1
Antoniou, M; Freund, R; Ogale, S; Zerbini, CEH	1
Araujo, JM; Gomez, AC; Pinto, JA; Raez, LE; Rolfo, C	1
Lassen, U; Rohrberg, KS	1
Bentley, D; Brink, A; Buchheit, V; Chow-Maneval, E; Djebli, N; Guerini, E; Kowalski, K; Meneses-Lorente, G; Mercier, F; Phipps, A; Yu, L	1
Álvarez, R; Bautista, F; Colomer, R; de Álava, E; Garrido, P; Hladun, R; López-Ríos, F; Rojo, F	1
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N	1
Ahn, MJ; Barlesi, F; Chen, D; Chiu, CH; Cho, BC; Day, BM; De Braud, F; Doebele, RC; Drilon, A; Dziadziuszko, R; Farago, AF; Karapetis, CS; Krebs, MG; Li, YC; Lin, CC; Liu, SV; Patel, MR; Siena, S; Wilson, TR	1
Antoniou, M; Bennett, I; Blay, JY; Hong, D; Krebs, MG; Le Tourneau, C; Veronese, L	1
Delgado, J; Enzmann, H; Josephson, F; Melchiorri, D; Migali, C; Pean, E; Pignatti, F	1
Brandi, G; Rizzo, A	1
Frampton, JE	1
Bui, NQ; Chawla, N; Seetharam, M	1
Ahn, MJ; Barlesi, F; Chen, D; Conley, A; Demetri, G; Doebele, R; Drilon, A; Kapre, A; McCallum, S; Osborne, S; Paz-Ares, L; Rolfo, C; Seto, T; Siena, S; Wolf, J	1
Bauer, S; Dieckmann, N; Schildhaus, HU	1
Florou, V; Garrido-Laguna, I; Gilcrease, GW; Maeda, P; Nevala-Plagemann, C; Whisenant, J	1
Aust, D; Folprecht, G; Fröhling, S; Glimm, H; Hanf, D; Heining, C; Herbst, F; Hutter, B; Jahn, A; Laaber, K; Nebelung, H; Richter, D; Uhrig, S	1
Beydoun, N; Cooper, W; Kasherman, L; Liu, Q; Lu, M; Lynch, J; Woodford, R	1
Chen, DH; Fonseca, M; Ghosh, AK; Walker, JM	1
Domoto, H; Hashiguchi, MH; Hiroshima, Y; Kagyo, J; Kato, T; Matsuzaki, T; Nakahara, Y; Sato, T; Shiomi, T; Watanabe, R; Yokose, T	1
Brink, A; Buchheit, V; Chow-Maneval, E; Djebli, N; Fowler, S; Guerini, E; Kowalski, K; Meneses-Lorente, G; Mercier, F; Phipps, A; Ullah, M; Umehara, K; Yu, L; Zwanziger, E	1
Araujo-Mino, E; Bardia, A; Dowlati, A; Drilon, A; Eshaghian, S; Gandara, DR; Gettinger, S; Goldberg, S; Hong, D; Kiedrowski, L; Lin, JJ; Liu, SV; McCoach, C; Mobayed, M; Morse, M; Nguyen, T; Nieva, JJ; Price, K; Rolfo, C; Russo, A; Sashital, D; Schram, AM; Stinchcombe, T; Subramanian, J; Vidula, N	1
Buchheit, V; Cleary, Y; Djebli, N; Fowler, S; Frey, N; Guerini, E; Meneses-Lorente, G; Mercier, F; Parrott, N; Phipps, A; Yu, L	1
Osman, HM; Tuncbilek, M	1
Bonnefois, G; Buchheit, V; Djebli, N; Frey, N; González-Sales, M; Meneses-Lorente, G; Mercier, F; Tremblay, PO	1
Balhara, A; Dhiman, V; Golla, VM; Kushwah, BS; Samanthula, G; Singh, S; Velip, L	1
Bennett, I; Krebs, MG	1
Byun, JH; Cho, HJ; Choi, E; Han, DG; Jung, IH; Park, T; Seo, SW; Yoon, IS	1
Hatswell, AJ; Sullivan, WG	1
Ayinampudi, V; Buzón, MJ; Genescà, M; Grau-Expósito, J; Peralta-Garcia, A; Perea, D; Selent, J; Stepniewski, TM; Torrens-Fontanals, M; Waldhoer, M; Zimmermann, M	1
Harada, H; Iwai, H; Kanda, A; Kawahara, A; Ohe, C; Sawada, S; Sengupta, B; Suzuki, K; Takeda, M; Uemura, Y	1
Kim, BJ; Kim, HS; Sohn, SH; Sul, HJ; Zang, DY	1
Agoni, C; Ibrahim, MAA; Issahaku, AR; Manimbulu, N; Salifu, EY; Soliman, MES	1
Djos, A; Elfman, LHM; Fransson, S; Gordon Murkes, L; Guan, J; Hallberg, B; Johnsen, JI; Kogner, P; Martinsson, T; Mendoza-García, P; Palmer, RH; Siaw, JT; Stenman, JJE; Treis, D; Umapathy, G; Wessman, S	1
Djebli, N; González-Sales, M; Jaminion, F; Meneses-Lorente, G; Mercier, F	1
Ahn, MJ; Bazhenova, L; Chawla, SP; Chen, D; Chiu, CH; Cho, BC; De Braud, F; Demetri, GD; Drilon, A; Dziadziuszko, R; Fakih, M; Goto, K; Heinzmann, S; John, T; Lee, J; Lin, JJ; Liu, SV; Patel, MR; Pitcher, B; Rolfo, C; Seto, T; Siena, S; Wilson, TR	1
Artemov, A; Druy, A; Hwang, EI; Imyanitov, E; Karachunsky, A; Kislyakov, A; Maschan, A; Novichkova, G; Packer, RJ; Panferova, A; Papusha, L; Salnikova, E; Valiakhmetova, A; Zaytseva, M	1
Brose, MS; Carlson, JJ; Federman, N; Italiano, A; Kummar, S; Lassen, U; Sullivan, SD	1
Bartolome, L; Camidge, DR; Cappelleri, JC; Daniele, P; Groff, M; Iadeluca, L; Tremblay, G; Usari, T; Wilner, K; Wiltshire, R	1
Barlesi, F; Chang, CW; Choeurng, V; Dennis, L; Doebele, RC; Drilon, A; Dziadziuszko, R; Hung, T; Li, M; Riehl, T; Simmons, B; Skoletsky, J; Wang, K; Wilson, TR; Woodhouse, R; Wu, C	1
Arai, S; Fukuda, K; Kotani, H; Nishiyama, A; Ohtsubo, K; Omori, K; Suzuki, C; Tajima, A; Takeuchi, S; Takumi, Y; Tange, S; Tanimoto, A; Yamamoto, N; Yanagimura, N; Yano, S	1
Abdelbaki, MS; Armstrong, AE; Basu, EM; Bergthold, G; Cardenas, A; Caron, H; Cash, T; Chohan, S; Chow Maneval, E; Corradini, N; Desai, AV; Devlin, C; Farid-Kapadia, M; Foster, JH; Fox, E; Gajjar, A; Gauvain, K; Hutchinson, KE; Macy, ME; Maese, L; Marshall, LV; Meneses-Lorente, G; Pratilas, CA; Robinson, GW; Sabnis, AJ; Shusterman, S; Weiss, BD; Whipple, NS; Yoon, J	1
Chen, L; Jiang, Q; Li, H; Li, M	1
Chandarana, SP; Ernst, MS; Hao, D; Hyrcza, MD; Lysack, JT	1
Carlson, JJ; Suh, K; Sullivan, SD; Williamson, T; Xia, F	1
Cappabianca, L; Farina, AR; Mackay, AR; Ruggieri, M; Sbaffone, M; Sebastiano, M; Zelli, V	1
Hashimoto, N; Iehara, T; Konishi, E; Miyachi, M; Shishido-Hara, Y; Sugimoto, Y; Sugitatsu, Y; Tomida, A; Tsuchiya, K; Umebayashi, D; Yamanaka, T; Yoshida, H	1
Huygens, S; Koleva-Kolarova, R; Nagy, B; Rutten-van Mölken, M; Szilberhorn, L; Vellekoop, H; Versteegh, M; Wordsworth, S; Zelei, T	1

Reviews

25 review(s) available for indazoles and entrectinib

Article	Year
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert opinion on investigational drugs, 2015, Volume: 24, Issue:11 Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptor, trkB; Receptor, trkC	2015
Targeting TRK family proteins in cancer. Pharmacology & therapeutics, 2017, Volume: 173 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Humans; Indazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC	2017
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer treatment reviews, 2017, Volume: 55 Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones	2017
Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features. Hematology (Amsterdam, Netherlands), 2018, Volume: 23, Issue:9 Topics: Benzamides; ETS Translocation Variant 6 Protein; Gene Rearrangement; Humans; Indazoles; Leukemia, Myeloid, Acute; Mutation; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-ets; Repressor Proteins; Staurosporine; Tumor Microenvironment	2018
Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug design, development and therapy, 2018, Volume: 12 Topics: Anaplastic Lymphoma Kinase; Animals; Benzamides; Humans; Indazoles; Neuroblastoma; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases	2018
Entrectinib: First Global Approval. Drugs, 2019, Volume: 79, Issue:13 Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors	2019
Revisiting NTRKs as an emerging oncogene in hematological malignancies. Leukemia, 2019, Volume: 33, Issue:11 Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Indazoles; Mice; Oncogenes; Point Mutation; Prognosis; Pyrazoles; Pyrimidines; Receptor, trkA; Zebrafish	2019
TRK inhibitors in TRK fusion-positive cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 11-01, Volume: 30, Issue:Suppl_8 Topics: Animals; Antineoplastic Agents; Benzamides; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Indazoles; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases	2019
How I treat ESMO open, 2019, Volume: 4, Issue:Suppl 2 Topics: Benzamides; Biomarkers, Tumor; Gene Fusion; Genetic Testing; Humans; Indazoles; Neoplasms; Patient Selection; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Nerve Growth Factor; Time Factors; Treatment Outcome	2019
[NTRK Fusions: A new way of treatment for gastro-intestinal tumor?] Bulletin du cancer, 2020, Volume: 107, Issue:4 Topics: Benzamides; Colorectal Neoplasms; Gastrointestinal Neoplasms; Gene Fusion; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization; Indazoles; Membrane Glycoproteins; Nerve Growth Factors; Oncogene Proteins; Oncogene Proteins, Fusion; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC	2020
Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019. Expert opinion on therapeutic patents, 2020, Volume: 30, Issue:5 Topics: Animals; Benzamides; Drug Design; Drug Development; Humans; Indazoles; Membrane Glycoproteins; Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC	2020
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert review of anticancer therapy, 2020, Volume: 20, Issue:5 Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Disease Progression; Gene Fusion; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2020
Tropomyosin receptor kinase inhibitors in the management of sarcomas. Current opinion in oncology, 2020, Volume: 32, Issue:4 Topics: Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Indazoles; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkC; Sarcoma	2020
Evaluating entrectinib as a treatment option for non-small cell lung cancer. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:16 Topics: Administration, Oral; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Treatment Outcome	2020
Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:8 Topics: Adult; Benzamides; Delivery of Health Care; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases	2020
Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date. Hematology/oncology and stem cell therapy, 2021, Volume: 14, Issue:3 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins	2021
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. Drugs, 2021, Volume: 81, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA	2021
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearr ESMO open, 2021, Volume: 6, Issue:2 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Gene Fusion; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Amino Acid	2021
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC. Drugs, 2021, Volume: 81, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, trkA	2021
Evolving role of entrectinib in treatment of Future oncology (London, England), 2021, Volume: 17, Issue:22 Topics: Animals; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Drug Approval; Drug Evaluation, Preclinical; Humans; Indazoles; Membrane Glycoproteins; Molecular Targeted Therapy; Neoplasms; Oncogene Proteins, Fusion; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC	2021
Tropomyosin receptor kinases in sarcomas - of joy and despair. Current opinion in oncology, 2021, 07-01, Volume: 33, Issue:4 Topics: Benzamides; Humans; Indazoles; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Sarcoma	2021
Disseminated intravascular coagulation complicating diagnosis of ROS1-mutant non-small cell lung cancer: A case report and literature review. Thoracic cancer, 2021, Volume: 12, Issue:17 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Disseminated Intravascular Coagulation; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2021
Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors. Current medicinal chemistry, 2022, Volume: 29, Issue:15 Topics: Adult; Benzamides; Child; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases	2022
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. The American journal of managed care, 2022, Volume: 28, Issue:2 Suppl Topics: Benzamides; Gene Fusion; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines	2022
Entrectinib, a new multi-target inhibitor for cancer therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 150 Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases	2022

Trials

6 trial(s) available for indazoles and entrectinib

Article	Year
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:8 Topics: Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Survival Rate; Treatment Outcome	2020
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. Investigational new drugs, 2021, Volume: 39, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Capsules; Cross-Over Studies; Fasting; Feces; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Indazoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Therapeutic Equivalency; Young Adult	2021
Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO open, 2021, Volume: 6, Issue:2 Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms	2021
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO open, 2021, Volume: 6, Issue:3 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Patient Reported Outcome Measures; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Quality of Life	2021
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission. Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Follow-Up Studies; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Protein Kinase Inhibitors; Tissue Distribution; Young Adult	2021
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro-oncology, 2022, 10-03, Volume: 24, Issue:10 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Young Adult	2022

Other Studies

75 other study(ies) available for indazoles and entrectinib

Article	Year
Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget, 2015, Sep-15, Volume: 6, Issue:27 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Crizotinib; Female; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genomics; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Male; Middle Aged; Mutation; Phosphorylation; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Tissue Array Analysis; Young Adult	2015
NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget, 2015, Nov-17, Volume: 6, Issue:36 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Female; Gene Rearrangement; Humans; Immunohistochemistry; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Receptor, trkA; Tumor Cells, Cultured	2015
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer discovery, 2016, Volume: 6, Issue:1 Topics: Animals; Benzamides; Catalytic Domain; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Mice; Mutation; Neoplasm Transplantation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Receptor, trkA	2016
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:12 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cohort Studies; Female; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, trkA	2015
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. British journal of cancer, 2015, Dec-22, Volume: 113, Issue:12 Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Aspartate Carbamoyltransferase; Benzamides; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Colorectal Neoplasms; Dihydroorotase; Female; Gene Rearrangement; Humans; Indazoles; Middle Aged; Receptor Protein-Tyrosine Kinases	2015
Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells. Oncotarget, 2016, Feb-02, Volume: 7, Issue:5 Topics: Anaplastic Lymphoma Kinase; Apoptosis; Autophagy; Benzamides; Blotting, Western; Cell Cycle; Cell Movement; Cell Proliferation; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Indazoles; Neuroblastoma; Phosphorylation; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Wound Healing	2016
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer letters, 2016, Mar-28, Volume: 372, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Humans; Indazoles; Irinotecan; Membrane Glycoproteins; Mice, Nude; Neuroblastoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Temozolomide; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays	2016
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:5 Topics: Adult; Benzamides; Biomarkers, Tumor; Carcinoma, Acinar Cell; Clinical Trials as Topic; Crizotinib; Diagnosis, Differential; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization, Fluorescence; Indazoles; Mammary Analogue Secretory Carcinoma; Mutation; Oncogene Proteins, Fusion; Pyrazoles; Pyridines; Salivary Gland Neoplasms	2016
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Molecular cancer therapeutics, 2016, Volume: 15, Issue:4 Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Enzyme Activation; Humans; Indazoles; Magnetic Resonance Imaging; Male; Mice; Mice, Transgenic; Mortality; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Translocation, Genetic; Treatment Outcome; Xenograft Model Antitumor Assays	2016
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. Journal of medicinal chemistry, 2016, Apr-14, Volume: 59, Issue:7 Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Blotting, Western; Cell Membrane Permeability; Cell Proliferation; Crystallization; Crystallography, X-Ray; Dogs; Drug Discovery; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Microsomes, Liver; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptor, trkB; Receptor, trkC; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2016
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jun-01, Volume: 28, Issue:6 Topics: Anaplastic Lymphoma Kinase; Aspartate Carbamoyltransferase; Benzamides; Biomarkers, Tumor; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Colorectal Neoplasms; Dihydroorotase; Drug Resistance, Neoplasm; Female; Gene Fusion; Gene Rearrangement; Humans; Indazoles; Middle Aged; Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases	2017
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. Nature communications, 2017, 07-11, Volume: 8 Topics: Animals; Benzamides; Brevican; CRISPR-Cas Systems; Drug Screening Assays, Antitumor; Feasibility Studies; Female; Gene Editing; Glioma; Humans; Indazoles; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental; Oncogene Fusion; Primary Cell Culture; Receptor, trkA	2017
Activity of Entrectinib in a Patient With the First Reported Journal of the National Comprehensive Cancer Network : JNCCN, 2017, Volume: 15, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drugs, Investigational; Exons; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Intestinal Neoplasms; Intestine, Small; Low Back Pain; Male; Neoplasm Grading; Neuroendocrine Tumors; Oncogene Proteins, Fusion; Palliative Care; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiotherapy; Response Evaluation Criteria in Solid Tumors; Sequence Analysis, RNA; Treatment Outcome	2017
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in Molecular cancer therapeutics, 2018, Volume: 17, Issue:2 Topics: Animals; Benzamides; Cell Line, Tumor; Female; Humans; Indazoles; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Zebrafish	2018
Protective Effects of Flagellin A N/C Against Radiation-Induced NLR Pyrin Domain Containing 3 Inflammasome-Dependent Pyroptosis in Intestinal Cells. International journal of radiation oncology, biology, physics, 2018, 05-01, Volume: 101, Issue:1 Topics: Animals; Benzamides; Caspase 1; Caspase Inhibitors; Dipeptides; Female; Flagellin; Indazoles; Inflammasomes; Interleukin-1beta; Interleukins; Intestine, Small; Mice; Mice, Inbred BALB C; NLR Proteins; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrin Domain; Pyroptosis; Radiation Injuries, Experimental; Radiation-Protective Agents; Random Allocation; Reactive Oxygen Species	2018
Foretinib Overcomes Entrectinib Resistance Associated with the Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 05-15, Volume: 24, Issue:10 Topics: Amino Acid Substitution; Anilides; Animals; Benzamides; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Heterografts; Humans; Indazoles; Mice; Models, Molecular; Mutation; Oncogene Proteins, Fusion; Quinolines; Receptor, trkA; Structure-Activity Relationship	2018
Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nature communications, 2018, 04-13, Volume: 9, Issue:1 Topics: Animals; Antigens, Neoplasm; Benzamides; Brain Neoplasms; Brevican; CRISPR-Cas Systems; DNA Repair; False Positive Reactions; Gene Editing; Gene Frequency; Gene Transfer Techniques; Glioma; Humans; In Situ Hybridization, Fluorescence; Indazoles; Mice; Mice, SCID; Mice, Transgenic; Mutation; NIH 3T3 Cells; Receptor, trkA; RNA, Guide, Kinetoplastida	2018
LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation. Journal of pharmaceutical and biomedical analysis, 2018, Oct-25, Volume: 160 Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Development; Indazoles; Indolequinones; Male; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry	2018
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Investigational new drugs, 2020, Volume: 38, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras)	2020
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nature communications, 2019, 08-09, Volume: 10, Issue:1 Topics: Aminopyridines; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Development; Drug Resistance, Neoplasm; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Membrane Glycoproteins; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor, trkB	2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature medicine, 2019, Volume: 25, Issue:9 Topics: Adolescent; Adult; Animals; Benzamides; Cell Proliferation; Cell-Free Nucleic Acids; Child; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Imidazoles; Indazoles; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplasms; Oncogene Proteins, Fusion; Oximes; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Pyrimidines; Pyrimidinones; Receptor, trkA; Young Adult	2019
FDA notches up third tissue-agnostic cancer approval. Nature reviews. Drug discovery, 2019, Volume: 18, Issue:10 Topics: Benzamides; Drug Approval; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; United States; United States Food and Drug Administration	2019
New Drug Targets Key Genetic Driver of Cancer. The American journal of nursing, 2019, Volume: 119, Issue:12 Topics: Benzamides; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2019
Site-agnostic biomarker-guided oncology drug development. Expert review of molecular diagnostics, 2020, Volume: 20, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Clinical Decision-Making; Clinical Trials as Topic; Drug Approval; Drug Development; Humans; Indazoles; Molecular Targeted Therapy; Neoplasms; Organ Specificity; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic	2020
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology, 2020, Volume: 21, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Gene Fusion; Humans; Indazoles; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors; Receptor, trkA; Receptor, trkB; Receptor, trkC; Receptors, Nerve Growth Factor; Time Factors; Treatment Outcome	2020
Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours. The Lancet. Oncology, 2020, Volume: 21, Issue:2 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2020
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. The Lancet. Oncology, 2020, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Gene Fusion; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Time Factors	2020
Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model. Molecular cancer therapeutics, 2020, Volume: 19, Issue:3 Topics: Animals; Apoptosis; Benzamides; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mice, Nude; Neuroblastoma; Protein Kinase Inhibitors; Proteome; RNA-Seq; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020
On the right TRK: from oncogene discovery to cancer therapeutics. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, Volume: 30 Suppl 8 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Mice; Neoplasms; Oncogene Proteins, Fusion; Oncogenes; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA	2019
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. Blood, 2020, 06-11, Volume: 135, Issue:24 Topics: Animals; Base Sequence; Benzamides; Cell Line; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Indazoles; Lipid Metabolism; Membrane Glycoproteins; Mice; Mutant Proteins; Oncogenes; Point Mutation; Protein Kinase Inhibitors; Protein Multimerization; Receptor, trkB; Receptor, trkC; Recombinant Proteins; RNA, Small Interfering	2020
Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC). Current computer-aided drug design, 2021, Volume: 17, Issue:3 Topics: Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Design; Humans; Indazoles; Lung Neoplasms; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2021
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro-oncology, 2020, 06-09, Volume: 22, Issue:6 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Differentiation; Indazoles; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats	2020
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib. The AAPS journal, 2020, 05-26, Volume: 22, Issue:4 Topics: Adult; Benzamides; Female; Food; Food-Drug Interactions; Gastric Absorption; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Indazoles; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Young Adult	2020
Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. Biochemical pharmacology, 2020, Volume: 178 Topics: A549 Cells; Animals; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytostatic Agents; Dogs; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Indazoles; Madin Darby Canine Kidney Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Secondary	2020
Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:8 Topics: Aminopyridines; Benzamides; Central Nervous System; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles	2020
Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell reports, 2020, 08-04, Volume: 32, Issue:5 Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; HEK293 Cells; Humans; Indazoles; Lung Neoplasms; Male; Mice, Inbred NOD; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptor, trkA	2020
Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib. Anti-cancer drugs, 2020, Volume: 31, Issue:10 Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Benzamides; Gene Fusion; Granuloma, Plasma Cell; Humans; Indazoles; Inflammation; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pyrazoles; Treatment Failure; Tropomyosin	2020
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic ESMO open, 2020, Volume: 5, Issue:5 Topics: Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2020
FDA Approval Summary: Entrectinib for the Treatment of Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 02-15, Volume: 27, Issue:4 Topics: Benzamides; Drug Approval; Humans; Indazoles; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, trkA; Receptor, trkB; Receptor, trkC; United States; United States Food and Drug Administration	2021
Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system. Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:5 Topics: Acute Kidney Injury; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Azetidines; Benzamides; Female; Hospital Mortality; Hospitalization; Humans; Indazoles; Male; Middle Aged; Odds Ratio; Pharmacovigilance; Piperidines; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sirolimus; United States; United States Food and Drug Administration; Young Adult	2020
Agnostic biomarkers in gastrointestinal tumors: microsatellite instability and NTRK. Personalized medicine, 2021, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Female; Gastrointestinal Neoplasms; Humans; Immune Checkpoint Inhibitors; Indazoles; Male; Microsatellite Instability; Middle Aged; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines	2021
[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion]. Bulletin du cancer, 2020, Volume: 107, Issue:11 Topics: Adult; Benzamides; Child; Drug Approval; France; Humans; Indazoles; Membrane Glycoproteins; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC	2020
Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 02-15, Volume: 27, Issue:4 Topics: Adolescent; Adult; Animals; Benzamides; Cell Line, Tumor; Child; Desmoplastic Small Round Cell Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Male; Mice; Oncogene Proteins, Fusion; Receptor, trkC; RNA-Binding Protein EWS; WT1 Proteins; Xenograft Model Antitumor Assays; Young Adult	2021
A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER". Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:12 Topics: Benzamides; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines	2020
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:8 Topics: Adult; Age Factors; Benzamides; Child; Consensus; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Membrane Glycoproteins; Molecular Targeted Therapy; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC; Reverse Transcriptase Polymerase Chain Reaction; Societies, Medical; Spain	2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature communications, 2021, 02-24, Volume: 12, Issue:1 Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases	2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 04-10, Volume: 39, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Young Adult	2021
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks. Cancer treatment and research communications, 2021, Volume: 27 Topics: Benzamides; Bile Duct Neoplasms; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Indazoles; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Treatment Outcome	2021
Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. Journal of the National Comprehensive Cancer Network : JNCCN, 2021, Volume: 19, Issue:5 Topics: Aza Compounds; Benzamides; Drug Resistance, Neoplasm; Humans; Indazoles; Mammary Analogue Secretory Carcinoma; Oncogene Proteins, Fusion; Parotid Gland; Protein Kinase Inhibitors; Salivary Gland Neoplasms	2021
Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With JCO precision oncology, 2021, Volume: 5 Topics: Adult; Anilides; Benzamides; Drug Resistance, Neoplasm; ETS Translocation Variant 6 Protein; Gene Fusion; Humans; Indazoles; Male; Mutation; Proto-Oncogene Proteins c-ets; Pyridines; Receptor, trkC; Repressor Proteins; Thyroid Neoplasms; Treatment Outcome	2021
Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer. BMJ case reports, 2021, Jul-27, Volume: 14, Issue:7 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Lung Neoplasms; Middle Aged; Myocarditis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2021
A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib. Thoracic cancer, 2021, Volume: 12, Issue:18 Topics: Adenocarcinoma of Lung; Adult; Benzamides; Crizotinib; Female; Gene Rearrangement; Genomics; Humans; Indazoles; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2021
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). Investigational new drugs, 2022, Volume: 40, Issue:1 Topics: Adult; Antineoplastic Agents; Area Under Curve; Benzamides; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Half-Life; Healthy Volunteers; Hepatocytes; Humans; Indazoles; Male; Metabolic Clearance Rate; Middle Aged; Receptor Protein-Tyrosine Kinases	2022
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. British journal of cancer, 2022, Volume: 126, Issue:3 Topics: Benzamides; Biomarkers, Tumor; Circulating Tumor DNA; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Neoplasm Staging; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA	2022
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making. European journal of drug metabolism and pharmacokinetics, 2021, Volume: 46, Issue:6 Topics: Benzamides; Computer Simulation; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Indazoles	2021
Stress degradation study on entrectinib and characterization of its degradation products using HRMS and NMR. Journal of pharmaceutical and biomedical analysis, 2022, Jan-20, Volume: 208 Topics: Benzamides; Chromatography, High Pressure Liquid; Drug Stability; Hydrogen Peroxide; Hydrolysis; Indazoles; Oxidation-Reduction; Tandem Mass Spectrometry	2022
Response to comment on "Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications". ESMO open, 2021, Volume: 6, Issue:6 Topics: Benzamides; Humans; Indazoles; Neoplasms	2021
Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 146 Topics: Animals; Benzamides; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats	2022
Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'. ESMO open, 2021, Volume: 6, Issue:6 Topics: Benzamides; Humans; Indazoles; Neoplasms	2021
Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. International journal of molecular sciences, 2021, Dec-18, Volume: 22, Issue:24 Topics: Animals; Antiviral Agents; Benzamides; Cell Line; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Indazoles; Lung; Molecular Docking Simulation; SARS-CoV-2; Vero Cells; Virus Attachment	2021
Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report. BMC medical genomics, 2022, 01-06, Volume: 15, Issue:1 Topics: Benzamides; Biomarkers, Tumor; Carcinoma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Salivary Gland Neoplasms; Treatment Outcome	2022
Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression. International journal of molecular sciences, 2021, Dec-30, Volume: 23, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Middle Aged; Neoplasm Proteins; Receptor, trkA; RNA, Messenger; Stomach Neoplasms	2021
Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases. Cell biochemistry and biophysics, 2022, Volume: 80, Issue:1 Topics: Anaplastic Lymphoma Kinase; Benzamides; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Tyrosine	2022
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation. JCO precision oncology, 2022, Volume: 6 Topics: Anaplastic Lymphoma Kinase; Benzamides; Chromosomes, Human, Pair 2; Cytokines; Genetic Variation; Germ Cells; Humans; Indazoles; Infant; Male; Neuroblastoma; Protein Kinase Inhibitors; Receptor, trkA	2022
Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:3 Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Neoplasms, Second Primary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases	2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-01, Volume: 28, Issue:7 Topics: Adult; Benzamides; Carcinoma, Non-Small-Cell Lung; Child; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2022
Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib. Neuro-oncology, 2022, 06-01, Volume: 24, Issue:6 Topics: Benzamides; Carrier Proteins; Glioma; Humans; Indazoles; Infant; Lung Neoplasms; Nuclear Proteins; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2022
Effectiveness of crizotinib versus entrectinib in Future oncology (London, England), 2022, Volume: 18, Issue:17 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Humans; Indazoles; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Treatment Outcome	2022
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib. Molecular oncology, 2022, Volume: 16, Issue:10 Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Genomics; Humans; Indazoles; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins	2022
Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells. Cancer science, 2022, Volume: 113, Issue:7 Topics: Benzamides; Brain Neoplasms; ErbB Receptors; Humans; Indazoles; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Receptor, trkA	2022
TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report. Current oncology (Toronto, Ont.), 2022, 05-31, Volume: 29, Issue:6 Topics: Benzamides; Breast Neoplasms; Carcinoma; Gene Fusion; Humans; Indazoles	2022
Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic Journal of comparative effectiveness research, 2022, Volume: 11, Issue:14 Topics: Benzamides; Brain Neoplasms; Clinical Trials as Topic; Gene Fusion; Humans; Indazoles; Pyrazoles; Pyrimidines	2022
Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells. International journal of molecular sciences, 2022, Sep-17, Volume: 23, Issue:18 Topics: Alternative Splicing; Benzamides; Calmodulin; Cell Line, Tumor; Crizotinib; Doxorubicin; Humans; Indazoles; Neuroblastoma; Oxygen; Proto-Oncogene Proteins c-akt; Receptor, trkA; Ryanodine Receptor Calcium Release Channel	2022
Entrectinib treatment induces a durable response against ARHGEF11::NTRK1 fusion gene-positive spinal cord diffuse pediatric-type high-grade glioma. Pediatric blood & cancer, 2023, Volume: 70, Issue:10 Topics: Benzamides; Child; Glioma; Humans; Indazoles; Rho Guanine Nucleotide Exchange Factors; Spinal Cord	2023
Cost-effectiveness of alternative Personalized medicine, 2023, Volume: 20, Issue:4 Topics: Adult; Benzamides; Cost-Benefit Analysis; Europe; Humans; Indazoles; Neoplasms	2023